ContraFect Corporation (NASDAQ:CFRX) will issue its quarterly earnings data on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
ContraFect Corporation (NASDAQ:CFRX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. On average, analysts expect ContraFect Corporation to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ContraFect Corporation (NASDAQ:CFRX) opened at $1.02 on Monday. ContraFect Corporation has a fifty-two week low of $0.80 and a fifty-two week high of $2.70.
COPYRIGHT VIOLATION WARNING: “ContraFect Corporation (CFRX) Set to Announce Quarterly Earnings on Tuesday” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/06/contrafect-corporation-cfrx-set-to-announce-quarterly-earnings-on-tuesday.html.
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.